Literature DB >> 20065653

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Donna L Montgomery1, Ying-Jie Wang, Renee Hrin, Micah Luftig, Bin Su, Michael D Miller, Fubao Wang, Peter Haytko, Lingyi Huang, Salvatore Vitelli, Jon Condra, Xiaomei Liu, Richard Hampton, Andrea Carfi, Antonello Pessi, Elisabetta Bianchi, Joseph Joyce, Chris Lloyd, Romas Geleziunas, David Bramhill, Vicki M King, Adam C Finnefrock, William Strohl, Zhiqiang An.   

Abstract

The human D5 monoclonal antibody binds to the highly conserved hydrophobic pocket on the N-terminal heptad repeat (NHR) trimer of HIV-1 gp41 and exhibits modest yet relatively broad neutralization activity. Both binding and neutralization depend on residues in the complementarity determining regions (CDRs) of the D5 IgG variable domains on heavy chain (VH) and light chain (VL). In an effort to increase neutralization activity to a wider range of HIV-1 strains, we have affinity matured the parental D5 scFv by randomizing selected residues in 5 of its 6 CDRs. The resulting scFv variants derived from four different CDR changes showed enhanced binding affinities to gp41 NHR mimetic (5-helix) which correlated to improved neutralization potencies by up to 8-fold. However, when converted to IgG1s, these D5 variants had up to a 12-fold reduction in neutralization potency over their corresponding scFvs despite their slightly enhanced in vitro binding affinities. Remarkably, D5 variant IgG1s bearing residue changes in CDRs that interact with epitope residues N-terminal to the hydrophobic pocket (such as VH CDR3 and VL CDR3) retained more neutralization potency than those containing residue changes in pocket-interacting CDRs (such as VH CDR2). These results provide compelling evidence for the existence of a steric block to an IgG that extends to the gp41 NHR hydrophobic pocket region, and can be a useful guide for developing therapeutic antibodies and vaccines circumventing this block.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20065653      PMCID: PMC2759496          DOI: 10.4161/mabs.1.5.9214

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  35 in total

1.  Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

Authors:  Y Kliger; Y Shai
Journal:  J Mol Biol       Date:  2000-01-14       Impact factor: 5.469

2.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

3.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 4.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 5.  Phage display of antibody fragments.

Authors:  A Pini; L Bracci
Journal:  Curr Protein Pept Sci       Date:  2000-09       Impact factor: 3.272

6.  Improving biosensor analysis.

Authors:  D G Myszka
Journal:  J Mol Recognit       Date:  1999 Sep-Oct       Impact factor: 2.137

Review 7.  Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.

Authors:  Renee Hrin; Donna L Montgomery; Fubao Wang; Jon H Condra; Zhiqiang An; William R Strohl; Elisabetta Bianchi; Antonello Pessi; Joseph G Joyce; Ying-Jie Wang
Journal:  AIDS Res Hum Retroviruses       Date:  2008-12       Impact factor: 2.205

8.  Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Authors:  Maxime Moulard; Sanjay K Phogat; Yuuei Shu; Aran F Labrijn; Xiaodong Xiao; James M Binley; Mei-Yun Zhang; Igor A Sidorov; Christopher C Broder; James Robinson; Paul W H I Parren; Dennis R Burton; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

9.  Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Igor A Sidorov; John M Louis; Ilia Harris; Antony S Dimitrov; Peter Bouma; Fatim Cham; Anil Choudhary; Susanna M Rybak; Timothy Fouts; David C Montefiori; Christopher C Broder; Gerald V Quinnan; Dimiter S Dimitrov
Journal:  Virology       Date:  2007-02-15       Impact factor: 3.616

Review 10.  Challenges in the development of an HIV-1 vaccine.

Authors:  Dan H Barouch
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

View more
  15 in total

1.  Pharmacological applications of a novel neoepitope antibody to a modified amyloid precursor protein-derived beta-secretase product.

Authors:  Guoxin Wu; Sethu Sankaranarayanan; Donna L Montgomery; Adam J Simon; Zhiqiang An; Mary J Savage
Journal:  Protein Cell       Date:  2011-08-06       Impact factor: 14.870

2.  Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets.

Authors:  Tracy R Clinton; Matthew T Weinstock; Michael T Jacobsen; Nicolas Szabo-Fresnais; Maya J Pandya; Frank G Whitby; Andrew S Herbert; Laura I Prugar; Rena McKinnon; Christopher P Hill; Brett D Welch; John M Dye; Debra M Eckert; Michael S Kay
Journal:  Protein Sci       Date:  2014-10-31       Impact factor: 6.725

Review 3.  Monoclonal antibody-based candidate therapeutics against HIV type 1.

Authors:  Weizao Chen; Dimiter S Dimitrov
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

4.  Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.

Authors:  Guo-Gang Shang; Jian-Hua Zhang; Yong-Gang Lü; Jun Yun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

5.  Contribution of light chain residues to high affinity binding in an HIV-1 antibody explored by combinatorial scanning mutagenesis.

Authors:  Gustavo F Da Silva; Joseph S Harrison; Jonathan R Lai
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

6.  A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.

Authors:  Yan G Ni; Stefania Di Marco; Jon H Condra; Laurence B Peterson; Weirong Wang; Fubao Wang; Shilpa Pandit; Holly A Hammond; Ray Rosa; Richard T Cummings; Dana D Wood; Xiaomei Liu; Matthew J Bottomley; Xun Shen; Rose M Cubbon; Sheng-ping Wang; Douglas G Johns; Cinzia Volpari; Lora Hamuro; Jayne Chin; Lingyi Huang; Jing Zhang Zhao; Salvatore Vitelli; Peter Haytko; Douglas Wisniewski; Lyndon J Mitnaul; Carl P Sparrow; Brian Hubbard; Andrea Carfí; Ayesha Sitlani
Journal:  J Lipid Res       Date:  2010-10-19       Impact factor: 5.922

7.  Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV).

Authors:  Alexander Waechter; Joachim Denner
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

8.  A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.

Authors:  David Wensel; Yongnian Sun; Jonathan Davis; Zhufang Li; Sharon Zhang; Thomas McDonagh; David Fabrizio; Mark Cockett; Mark Krystal
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

9.  Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.

Authors:  Elena Gustchina; Mi Li; John M Louis; D Eric Anderson; John Lloyd; Christian Frisch; Carole A Bewley; Alla Gustchina; Alexander Wlodawer; G Marius Clore
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

10.  Side chain requirements for affinity and specificity in D5, an HIV-1 antibody derived from the VH1-69 germline segment.

Authors:  Alex Stewart; Joseph S Harrison; Lauren K Regula; Jonathan R Lai
Journal:  BMC Biochem       Date:  2013-04-08       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.